Profile: ID Biomedical Corp. distributes diagnostic test systems. We focused on the development of vaccines based on its proprietary proteosome intranasal delivery technology. We provide vaccines for the pre-clinical development of grass & tree pollen allergies and bacteria that causes plague pneumonia. We market fluviral, an injectable vaccine for influenza and neisVac-C for meningococcal group C disease. Our product line includes fluinsure, a nonlive intranasally delivered vaccine for the prevention of influenza; streptAvax, a subunit injectable vaccine for the prevention of diseases caused by group A streptococcus in children; and PGCvax, a subunit injectable vaccine for the prevention of diseases caused by atreptococcus pneumoniae.
The company was founded in 1991, has revenues of < USD 1 Million, has ~50 employees. NASDAQ:TSE (SEC Filings)
1 Products/Services (Click for related suppliers)
|
| • Nucleic Acid Amplification Test for Chlamydia (FDA Code: MKZ / 866.3120) Chlamydia serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to chlamydia in serum. Additionally, some of these reagents consist of chlamydia antisera conjugated with a fluorescent dye used to identify chlamydia directly from clinical specimens or cultured isolates derived from clinical specimens. The identification aids in the diagnosis of disease caused by bacteria belonging to the genusChlamydia and provides epidemiological information on these diseases. Chlamydia are the causative agents of psittacosis (a form of pneumonia), lymphogranuloma venereum (a venereal disease), and trachoma (a chronic disease of the eye and eyelid). |